Bavarian Nordic A/S – Major Shareholder Announcement

KVISTGAARD, Denmark, April 24, 2013 - Bavarian Nordic A/S (OMX: BAVA) has received information from OrbiMed Advisors LLC that the company has decreased its ownership in Bavarian Nordic from 5.35 % to 4.53 % of the shares and voting rights in Bavarian Nordic.

Asger Aamund

Chairman of the Board 

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64 

About Bavarian Nordic
Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline targets cancer and infectious diseases, and includes ten development programs. In oncology, the company’s lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In clinical Phase 1 and Phase 2 trials, PROSTVAC® has been tested in nearly 600 patients. In infectious diseases, the company’s lead program is IMVAMUNE®, a non-replicating smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government. For more information, visit

Company Announcement no. 11 / 2013